Do you want to read an article? Please log in or register.
Efficacy and Safety of Dupilumab in Children With Moderate-to-Severe Asthma: A Systematic Review of Emerging Phase 3 Evidence
Asthma
Related content
Asthma
Effects of Dupilumab in Children and Adolescents With Moderate-Severe Asthma: A Systematic Review of Clinical Trials
Pediatr Pulmonol
Aznaran-Torres R, Nombera-Lossio J, Arredondo-Nontol M, Jurado-Hernández JL, Álvarez-Orozco IF, Rojas EM, Taype-Rondan A, Fernandez-Guzman D
doi: 10.1002/ppul.71138
RECOMMENDED
COPD
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, Papi A, Pavord ID, Molfino NA, Almqvist G, Kotalik A, Hellqvist Å, Gołąbek M, Sindhwani NS, Ponnarambil SS, COURSE study investigators
doi: 10.1016/S2213-2600(24)00324-2
Asthma
Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)
Allergy Asthma Immunol Res
Park SY, Lee D, Kim JH, Lee Y, Ban GY, Sim DW, Kwon JW, Kim SR, Song WJ, Park HW, Chang YS, Koh YI, Lee BJ, Park HS, Cho YS, Kim SH
doi: 10.4168/aair.2025.17.3.384
RECOMMENDED
Asthma
Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Patel C, Sheth V, Koppula R, Kumar A, Bhate AS, Sahoo D, Jain MK, Mondal A, Parmar D, Kansagra K, Shrivastava R, Pathak H
doi: 10.1016/j.rmed.2025.108293
COMMENTED
COPD
Efficacy and safety of ensifentrine in treatment of COPD: a systematic review and meta-analysis of clinical trials
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended and commented by
Dr Marcus Hesse, Faculty Member
Ther Adv Respir Dis
Hammadeh BM, Younis OM, Alsufi MI, Idrees M, Hussein AM, Aldalati AY, Qtaishat FA, Qatawneh B, Bugazia A, Hamed RA
doi: 10.1177/17534666251347775
Asthma
Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma: The VESTIGE Trial
Am J Respir Crit Care Med
Porsbjerg C, Dunican EM, Lugogo NL, Castro M, Papi A, Backer V, Brightling CE, Bourdin A, Virchow JC, Zhang M, Soler X, Rowe PJ, Deniz Y, de Prado Gómez L, Sacks HJ, Jacob-Nara JA
doi: 10.1164/rccm.202410-1894OC
AsthmaRespiratory Tract Infection
Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register
Respir Med
Hansen S, Håkansson KEJ, Soendergaard MB, Bjerrum AS, Schmid JM, Johansson SL, Rasmussen LM, Johnsen CR, von Bülow A, Bonnesen B, Krogh NS, Hilberg O, Dongo L, Vijdea R, Ulrik CS, Porsbjerg C
doi: 10.1016/j.rmed.2025.108203
Further Publications
Efficacy of dupilumab and mepolizumab in eosinophilic COPD: insights from phase 3 trials
Respir Med
Suter P, Greig R, Chan R, Lipworth B
doi: 10.1016/j.rmed.2025.108343
RECOMMENDED
Asthma
Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: A Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Allergy Asthma Immunol Res
Chen R, Dai Y, Yang D, Liu C, Han W, Gu W, Cao J, Zhou Q, Howarth P, Weng S, Xiong C, Huang J, Liang P, Zhong N, 201536 Study Group
doi: 10.4168/aair.2025.17.4.473